CRISPR/Cas in Viral Research 2024
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 981
Special Issue Editor
Interests: gene targeting; CRISPR-Cas; host genes; virus; antiviral strategy; hiv; crispr; SARS-CoV-2; HIV; Cas9; Cas12a; transient; RNP; HIV-host interaction; lentiviral vectors; TRIM5α; human immunodeficiency virus type 1 (HIV-1); C-peptide; miRNA
Special Issue Information
Dear Colleagues,
A decade ago, clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated proteins (Cas) were discovered and used for gene editing in mammalian cells. This revolutionary system has since found various applications in understanding, combating, and even engineering viruses. After that, many iterative gene targeting tools that reformed based on CRISPR/Cas have been widely developed, including base editor, prime editing, SHERLOCK, DETECTR, PAC-MAN, ABACAS, pfAGO, IscB proteins, OMEGA, and Fanzor et al. However, only a few of them have been used in viral research. In fact, these gene targeting tools would have played pivotal roles in several viral areas, such as viral genome editing, antiviral defense, viral pathogenesis, vaccine development, viral detection/diagnostics, viral evolution, and viral resistance. Overall, CRISPR/Cas has the potential to transform viral research by enabling precise genetic modifications, offering new insights into viral pathogenesis, and enhancing our ability to combat viral threats. As technology advances, CRISPR/Cas is expected to remain a key player in antiviral research, promising progress in the fight against infectious diseases. This Special Issue seeks to gather comprehensive research findings on CRISPR/Cas and related technologies in viral studies, encompassing all virus species. We welcome original research studies, methodologies, bioinformatics, and reviews related to the use of CRISPR/Cas in viral research.
Dr. Shuliang Chen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CRISPR/Cas
- gene targeting and antiviral defense
- viral genome editing
- viral detection and diagnostic
- viral pathogenesis
- vaccine development and antiviral drug discovery
- viral evolution
Related Special Issues
- CRISPR/Cas in Viral Research in Viruses (14 articles)
- Applications of CRISPR Technology in Virology 2018 in Viruses (15 articles)
